Rezdiffra (Resmetirom) vs Actos (Pioglitazone): Titration Speed and Tolerability Compared

How Each Drug Is Titrated

Resmetirom has no classic dose-escalation ladder. Pioglitazone does. That single difference shapes the first 8 weeks of treatment entirely differently for patients.

Resmetirom is started at 80 mg orally once daily and may be increased to 100 mg once daily after approximately 4 weeks if the 80 mg dose is tolerated. The FDA-approved prescribing information for Rezdiffra specifies that the drug be taken with food to reduce gastrointestinal side effects. The MAESTRO-NASH trial used both the 80 mg and 100 mg doses, and the 100 mg arm showed the stronger histologic benefit, making the one-step escalation clinically meaningful rather than a formality.

Pioglitazone follows a conventional thiazolidinedione escalation: start at 15 mg once daily, then increase by 15 mg every 4 to 8 weeks based on glycemic and tolerability response, with a ceiling of 45 mg per day. The PIVENS trial used 30 mg daily in non-diabetic NASH patients, a dose that some clinicians now consider the pragmatic target for MASLD given that the 45 mg dose adds more edema risk with modest additional liver benefit.

Resmetirom Titration Protocol in Practice

The 80-to-100 mg step is optional. Patients with persistent nausea at 80 mg can remain at that dose indefinitely. The Rezdiffra prescribing information on FDA.gov specifies no requirement to reach 100 mg, and the 80 mg dose showed statistically significant fibrosis improvement in MAESTRO-NASH (24.2% vs 14.2% placebo, P<0.001). Clinicians at most liver centers treat the 100 mg dose as a 4-week checkpoint rather than a mandatory target.

Pioglitazone Titration Protocol in Practice

The 15-to-30-to-45 mg ladder typically takes 8 to 16 weeks to complete. Fluid retention is dose-dependent, so clinicians who observe ankle edema at 30 mg often stop escalation there. Body weight should be checked at every dose step. Patients with pre-existing congestive heart failure are contraindicated from pioglitazone use regardless of dose, per FDA labeling. The American Diabetes Association 2024 Standards of Care note that pioglitazone's cardiovascular risk reduction data (PROactive trial) apply primarily to patients with established type 2 diabetes, not to the broader MASLD-without-diabetes population.

Tolerability Profiles: What Patients Actually Experience

The side-effect clusters for these two drugs barely overlap. Resmetirom causes predominantly gastrointestinal symptoms early in treatment. Pioglitazone causes weight and fluid changes that can persist for the entire treatment duration.

Resmetirom GI Side Effects

In MAESTRO-NASH (N=966 in the combined active arms), nausea occurred in 19.9% of the 100 mg group vs 9.9% of placebo. Diarrhea occurred in 17.5% vs 9.9%. Both effects were most frequent in weeks 1 through 4 and rarely led to discontinuation. Fewer than 3% of resmetirom-treated patients stopped the drug due to GI events. Taking the tablet with a moderate-fat meal reduced peak plasma concentration by roughly 35%, which correlates with lower GI symptom rates based on pharmacokinetic modeling in the Rezdiffra FDA medical review.

Liver enzyme elevations above three times the upper limit of normal occurred in 3.8% of the resmetirom 100 mg group in MAESTRO-NASH, compared to 1.5% in placebo. These elevations were mostly transient. Hepatic safety monitoring every 3 months for the first year is recommended by most hepatology centers, though the AASLD guidance on MASH does not yet mandate a specific monitoring interval for resmetirom post-approval.

Pioglitazone Weight and Fluid Effects

The mean weight gain with pioglitazone 30 mg in PIVENS was approximately 2.5 kg over 96 weeks. At 45 mg, weight gain of 3 to 5 kg is common in real-world cohorts. Peripheral edema affected roughly 7% of pioglitazone-treated patients in pooled registration trials, compared to 2% on placebo, per FDA pharmacovigilance data. Patients who already carry excess visceral adiposity, the dominant phenotype in MASLD, may find weight gain particularly difficult to accept.

Pioglitazone also carries a class-level signal for bone fracture risk in women. The FDA updated the Actos label in 2011 to include a warning about increased fracture risk in female patients taking any thiazolidinedione. This is a long-term tolerability issue that does not appear in the first titration weeks but accumulates over months to years of use.

Bladder Cancer Signal

A 10-year observational study from the FDA and Kaiser Permanente found a statistically significant increase in bladder cancer risk with more than 24 months of pioglitazone exposure. The absolute risk increase was small (approximately 40 additional cases per 100,000 patient-years), but the signal prompted the FDA to add a contraindication for patients with active bladder cancer and a precaution for those with a prior history. Resmetirom has no known bladder cancer association.

Liver Histology Outcomes: What the Trials Show

Histologic endpoints differ between the two key trials, which makes direct comparison imperfect. Resmetirom's MAESTRO-NASH used dual endpoints of MASH resolution without fibrosis worsening and fibrosis improvement of at least one stage. PIVENS used a NASH activity score composite.

MAESTRO-NASH Results

Harrison et al., NEJM 2024 reported that at 52 weeks:

• MASH resolution without fibrosis worsening: 25.9% (resmetirom 100 mg) vs 14.2% placebo
• Fibrosis improvement by at least one stage: 26.0% (100 mg) vs 14.2% placebo
• Both comparisons reached P<0.001

The 80 mg dose also outperformed placebo. MASH resolution: 24.2% vs 14.2%. The trial enrolled patients with F1b, F2, or F3 fibrosis, and the FDA approval specifically covers F2 and F3. Patients with compensated cirrhosis (F4) were excluded.

PIVENS Results

Sanyal et al., NEJM 2010 showed that pioglitazone 30 mg produced improvement in the NASH activity score in 34% of patients vs 19% on placebo (P<0.001) at 96 weeks. Fibrosis improvement occurred in 37% of pioglitazone patients vs 21% on placebo, though this difference did not reach the pre-specified significance threshold (P=0.08). The PIVENS population was non-diabetic; outcomes in diabetic MASLD patients taking pioglitazone may differ.

The 96-week treatment window in PIVENS vs the 52-week window in MAESTRO-NASH means pioglitazone required nearly twice as long to demonstrate its effect. Whether pioglitazone would show stronger fibrosis data at 52 weeks, or resmetirom would show further gains at 96 weeks, remains an open question.

Lipid and Metabolic Effects

Resmetirom's thyroid hormone receptor beta-agonism drives meaningful lipid lowering. In MAESTRO-NASH, LDL-C fell by a mean of 12.6% in the 100 mg group over 52 weeks. Triglycerides dropped by approximately 22.5%. Apolipoprotein B fell by 14.2%. These are additive benefits for a population with high cardiovascular risk.

Pioglitazone has a mixed lipid profile. It reliably lowers triglycerides and raises HDL-C, but LDL-C may rise slightly or remain unchanged, particularly in patients already on statin therapy. A meta-analysis in Diabetes Care found that pioglitazone raised HDL-C by approximately 5 mg/dL but had a neutral-to-modest adverse effect on LDL-C particle size and density. For MASLD patients with concurrent dyslipidemia, resmetirom's lipid-lowering profile is an additional clinical argument in its favor.

Pioglitazone does reduce insulin resistance. For MASLD patients with pre-diabetes or type 2 diabetes, that insulin-sensitizing effect on hemoglobin A1c and fasting glucose may be valuable in a way resmetirom does not replicate. The AACE/ACE Comprehensive Diabetes Management Algorithm positions pioglitazone as a preferred agent in type 2 diabetes with hepatic steatosis precisely because of this dual action.

Drug Interactions and Organ-Specific Cautions

Resmetirom Drug Interactions

Resmetirom is a substrate and inhibitor of several transporters. The FDA prescribing information notes that co-administration with cyclosporine, a strong OATP1B1/1B3 inhibitor, is contraindicated because it raises resmetirom exposure approximately 4-fold. Statins transported by OATP1B1/1B3, including rosuvastatin and atorvastatin, show modestly elevated plasma concentrations when combined with resmetirom. The label recommends using the lowest effective statin dose and monitoring for statin-related myopathy. Given that most MASLD patients are already on statins, this interaction requires attention at initiation.

Pioglitazone Drug Interactions

Pioglitazone is primarily metabolized by CYP2C8. Gemfibrozil, a potent CYP2C8 inhibitor, can increase pioglitazone AUC by up to 3-fold. The FDA Actos label recommends limiting pioglitazone to 15 mg daily when gemfibrozil is co-prescribed. Rifampin, a CYP2C8 inducer, reduces pioglitazone exposure by approximately 54%, potentially negating its hepatic efficacy. Both interactions are straightforward to manage but require medication reconciliation before starting the drug.

Which Patients Belong on Which Drug

The following framework reflects the current evidence base and can serve as a clinical decision aid pending formal head-to-head trial data.

Resmetirom (Rezdiffra) is the preferred choice when:

• The patient has biopsy-confirmed or non-invasive biomarker-confirmed MASH with F2 or F3 fibrosis, regardless of diabetes status
• LDL-C or triglyceride lowering is a co-goal
• The patient has heart failure or a history of bladder cancer that contraindicates pioglitazone
• The patient has obesity and cannot tolerate additional weight gain
• Faster histologic response is desired (52-week key data vs 96-week for pioglitazone)

Pioglitazone (Actos) may be preferred when:

• The patient has type 2 diabetes or pre-diabetes and glycemic benefit is a co-goal
• Cost is the dominant constraint (pioglitazone is generic and may cost less than $20/month vs approximately $2,000/month for Rezdiffra)
• The patient has F1 fibrosis where resmetirom is not FDA-approved
• The patient is male, without heart failure, and without bladder cancer history, so the tolerability concerns are less restrictive

Combination use is not yet supported by randomized trial data. The MAESTRO-NASH exclusion criteria did not prohibit pioglitazone use, so some patients in the trial may have been on background pioglitazone, but subgroup analysis for this overlap has not been published. Clinicians considering combination therapy should do so under a structured protocol with close monitoring.

Switching From Resmetirom to Pioglitazone

Patients who discontinue resmetirom due to cost, GI intolerance, or insurance denial may consider transitioning to pioglitazone. There is no pharmacokinetic wash-out requirement for resmetirom before starting pioglitazone; the half-life of resmetirom is approximately 4.6 hours, so drug-drug overlap is clinically negligible. Pioglitazone can begin at 15 mg the day after resmetirom is stopped.

The histologic benefits of resmetirom are not expected to persist indefinitely after discontinuation. Preclinical data and the mechanistic literature suggest that thyroid hormone receptor beta agonism requires continuous administration to maintain its effects on hepatic fat oxidation. Patients who switch should expect a reassessment of liver biomarkers (ALT, AST, FIB-4, or MRI-PDFF) at 12 to 16 weeks post-switch to confirm stability.

When switching in the opposite direction, from pioglitazone to resmetirom, the transition should include a baseline weight check and lipid panel, since resmetirom's LDL-lowering effect may allow statin dose reduction after 8 to 12 weeks.

Cost, Access, and Real-World Adherence

Resmetirom's list price at launch was approximately $47,400 per year in the United States. Most commercial insurance plans require prior authorization documenting F2 or F3 fibrosis by biopsy or validated non-invasive test. The manufacturer (Madrigal Pharmaceuticals) offers a patient assistance program, but real-world access data for the first 12 months post-approval are not yet published in peer-reviewed form.

Pioglitazone is generic. Cash price at major pharmacies runs approximately $10 to $25 per month for 30 mg tablets. No prior authorization is required, and it is available on all formularies. For patients in health systems with limited specialty pharmacy access, this cost gap may be the deciding clinical factor even before mechanism or efficacy enters the discussion.

Adherence data from the PIVENS long-term follow-up showed that approximately 18% of pioglitazone patients discontinued before week 96, primarily due to weight gain and edema. Resmetirom's 52-week discontinuation rate for any reason in MAESTRO-NASH was approximately 10% in the 100 mg group. Lower discontinuation rates at the primary endpoint suggest better short-term tolerability for resmetirom, though the 44-week difference in trial duration limits direct comparison.

Monitoring Requirements During Treatment

Monitoring on Resmetirom

• Liver function tests (ALT, AST) at baseline, 4 weeks, 12 weeks, then every 3 months for year 1
• Lipid panel at baseline and 12 weeks (to capture LDL-lowering response and adjust statin if needed)
• Thyroid-stimulating hormone at baseline; resmetirom's receptor selectivity for THR-beta reduces peripheral thyroid effects, but pharmacodynamic data suggest TSH monitoring is still warranted annually
• Pregnancy test before initiation; resmetirom is FDA Pregnancy Category not formally assigned but animal data showed fetal harm; effective contraception is required

Monitoring on Pioglitazone

• Body weight and signs of edema at every visit
• Liver function tests at baseline; routine monitoring is not required by labeling unless symptoms arise, per FDA Actos PI
• Hemoglobin A1c and fasting glucose every 3 months in diabetic patients
• Bone density (DEXA) annually in women on long-term therapy, per American Association of Clinical Endocrinology position statements
• Urinalysis with cytology if hematuria develops, given bladder cancer signal